🇺🇸 FDA
Patent

US 8563731

Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]jamino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor

granted A61PA61P11/00A61P11/06

Quick answer

US patent 8563731 (Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]jamino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor) held by Almirall, S.A. expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Almirall, S.A.
Grant date
Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61P, A61P11/00, A61P11/06, A61P43/00